BioWorld

July 12, 2004

Awaiting Approval For Surfaxin, Discovery Labs Accesses $75M

Although Discovery Laboratories Inc. has plenty of financial resources for near-term operations, the Doylestown, Pa.-based company secured a $75 million equity facility that it can access over the next three years. (BioWorld Today) Read More

TransTech Adding $30M To Extended Series E Financing

AMA Wants All Clinical Trial Results Entered In Database

Ligand's PPAR Drug Delayed By Field-Leveling' FDA Rule

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026